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Background: Cystic echinococcosis is a serious zoonotic infection worldwide caused by metacestodes of
Echinococcus gruanulosus. Mebendazole and albendazole are the only two drugs used in the treatment of this
disease with cure rates only about 30% due to the poor oral absorption. Thus an alternative treatment for this
disease is needed.
Methods: A mebendazole oily suspension (MBZ-OS) was prepared and orally administrated to mice infected with
echinococcus cysts for 8 months at 12.5 mg/kg and 25 mg/kg for 14 consecutive days. Mebendazole suspended in
1% tragacanth (MBZ-1% tragacanth) served as treated control. In addition, liver and serum samples were collected
from these treated mice (25 mg/kg) for histopathology examination and liver function test. For pharmacokinetic
analysis, plasma, parasite (cyst wall and cyst fluid) and tissue samples were collected at 0.25, 0.5, 1, 2, 4, 8, 16 and
24 h after orally administrating MBZ-OS and MBZ-1% tragacanth to E. granulosus-infected mice at 25 mg/kg. These
samples were then processed and quantitatively analyzed by HPLC.
Results: The administration of MBZ-OS resulted in a treatment efficacy with the cyst weight reductions higher than
80%, significantly better than the corresponding MBZ-1% tragacanth groups. The better treatment efficacy of
MBZ-OS was related to the higher drug concentration in plasma, parasites and tissues. It was also shown that the
injury of the liver was not significantly altered by taking MBZ-OS compared to the untreated control.
Conclusion: These findings demonstrate that MBZ-OS is a promising new formulation of MBZ for treatment of
hydatid diseases without showing significantly liver toxicity.
Keywords: Mebendazole oily suspension, Cystic echinococcosis, Treatment efficacy, Pharmacokinetics,
Histopathology examination, Liver function testBackground
Cystic echinococcosis (CE) is a life-threatening disease
with serious public health and economic concern world-
wide. Infections with Echinococcus granulosus, the
causative agent of CE, occur globally and mostly in the
Mediterranean area, South America, Russia, western
China, Europe and Japan [1,2]. In China, with approxi-
mately 380,000 cases nationwide, CE is endemic in at* Correspondence: zhang_haobing@163.com
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unless otherwise stated.least 23 provinces [3-5] and at least 50 million individ-
uals are under the risk of this disease [6]. The prolifera-
tion of metacestodes mainly located in liver and lung,
leading to the space-occupying lesions. However, the
initial phase of the infection is always asymptomatic for
many years or even permanently. Without effective
treatment, the development of cysts will eventually
result in organ malfunction and even death in many cases
[7-9]. The preferred treatment strategies for CE are
surgical resection of the parasite mass and puncture,
aspiration, injection, re-aspiration (PAIR). The other option
is chemotherapy with albendazole (ABZ) or mebendazole
(MBZ), the only two drugs recommended by WHO. Boths is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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benzimidazoles, while chemotherapy is the only option in
inoperable and recrudescent cases [9]. Moreover, for the
great majority of patients in the resource-poor remote
areas in China, anti-parasitic treatment remains the
primary choice [10].
ABZ and MBZ are considered to have parasitocidal
effect in vitro [11,12]. Nevertheless, according to the
reports from the clinical trials, the cure rates of MBZ
and ABZ in the treatment of CE were about 30%
[3,7,8,13-15]. The unsatisfied therapeutic results are
commonly attributed to the poor drug absorption rate
which results in low drug concentartions in plasma and
hydatid cysts after oral administration [16]. In addition,
for MBZ, the inactive metabolites produced in the liver
could be another possible reason contributing to the low
active drug level [17]. In order to improve cure rate, these
two benzimidazoles were recommended to be taken to-
gether with a fat-containing meal [9]. In some reports,
suspending benzimidazoles in oils increased the solubility
[18], the drug concentration in plasma, the bioavailability
[18-22] and even the treatment efficacy for infected ani-
mals [18,22,23]. In China, the albendazole-emulsion was
proved effective [24,25] and has already been widely used
in clinic. Due to the better effect of MBZ against E. granu-
losus metacestodes in vitro and in experimental therapy
proceeded in mice than ABZ [11,12,26,27], a superior
improvement of MBZ treatment efficacy could be achieved
by increasing the bioavailability.
Until now, some progress has been achieved on the
novel formulations of MBZ. Solid dispersion with poly-
ethylene glycol [28,29], β-cyclodextrin compounds (β-CD)
[30], capsule [31] or drug-povidone complexes [16] were
tested in rodents and showed enhanced bioavailabilities
compared with the parent drugs. And the improving effi-
cacy of solid dispersion with polyethylene glycol and drug-
povidone complexes for CE was also confirmed in some
studies [32,33]. However, these researches for MBZ for-
mulations have not been continued and eventually trans-
lated into clinical applications. Based on our previous
study [18], we prepared a MBZ oily suspension with oleic
acid, glycerol trioleate, soy bean oil, some surfactants and
preservatives in the present study. Subsequently, the treat-
ment efficacy, the drug concentrations in plasma, parasite
and tissues, and the influence on the liver were evaluated.Methods
Chemicals
MBZ powder with the purity over 99.0% was purchased
from Hanjiang Pharm. Co. (Hanzhong, China). MBZ stand-
ard and ABZ served as internal standard were purchased
from Sigma-Aldrich Co. (St. Louis, UAS). The glycerol
trioleate, oleic acid and soybean oil were provided byQianwei Oil Technology Co., Ltd. (Shanghai, China). All
other chemicals were of the analytical pure grade.
Parasites, animals and infection
Liver hydatid cysts were obtained from newly slaughtered
sheep at abattoirs in Xining, Qinghai province, China.
Protoscoleces of E. granulosus were collected aseptically
from the cysts, and kept in cyst fluid at 4°C for not more
than 3–4 days before use. Prior to infection, the collected
protoscoleces were rinsed 5–8 times with Hanks’ balanced
salt solution (HBSS) containing penicillin (500 U/ml) and
streptomycin (500 U/ml). Viability of the PSCs was con-
firmed by visual inspection through inverted microscopy
after staining by 0.1% methylene blue. A protoscoleces
survival rate of more than 95% was necessary before the
infection. Kunming strain mice were purchased from
SLAC Laboratory Animal (Shanghai, China). Animals
were kept at the animal facility and had free access to
rodent food and tap water throughout the study. After
one week acclimatization, the female mice with body
weight of 18–22 g were inoculated intraperitoneally with
2,000 protoscoleces individually.
Preparation of MBZ oily formulation
The MBZ oily formulation (MBZ-OS) were prepared by
suspending MBZ in the mixture of oleic acid, glycerol
trioleate, soybean oil, span 80, tween 80 and sorbic acid
at a concentration of 2.5 and 1.25 g/l (w/v) respectively,
while MBZ in 1% tragacanth (MBZ-1% tragacanth) at
the same concentration served as treated control. The
volume of each drug preparation administered to mice
was 10 ml/kg. All the drug suspensions were made with
bowl mill (Nanjing, China) at 220 rpm for 1 h.
Effect against secondary cysts of E. granulosus
Seventy-one mice inoculated with E. granulosus protosco-
leces for 8 months were divided into 5 groups of 10–17
mice. Two groups were treated orally with MBZ-OS at a
daily dose of 25 mg/kg and 12.5 mg/kg for 14 consecutive
days respectively, and two groups were treated with MBZ-1%
tragacanth as the same scheme. The remaining one group
of 17 mice infected but untreated served as control. Mice
were sacrificed two weeks post-treatment. Then the cysts in
the peritoneal cavity were isolated and removed for weigh-
ing. The efficacy was assessed by mean cyst weight and
mean cyst weight reduction as previously described [18].
Drug concentrations and pharmacokinetics of MBZ
formulation
Collection of plasma, cyst wall, cyst fluid and tissues samples
Forty-eight mice inoculated with E. granulosus protosco-
leces for 8 months were divided into two groups, one was
administered orally with MBZ-OS at a single dose of
25 mg/kg, and the other was treated orally with the same
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each group were bled at 0.25, 0.5, 1, 2, 4, 8, 16 and 24 h
post-administration. The plasma samples were collected
after centrifugation at 2583 x g for 15 minutes and then
stored immediately at −20°C pending HPLC analysis.
Then the hydatid cyst (parasite), heart, liver, spleen,
lung, kidney, intestine and brain of each mouse were rap-
idly excised after blood collection at the same time inter-
vals, while the cyst fluid was drawn from the hydatid cyst
by syringe, and then stored at −20°C. The tissues were
immediately washed twice with normal saline, wiped with
filter paper, weighed and homogenized with 1.0 ml of nor-
mal saline. The tissue samples were centrifuged at 2583 x g
for 15 minutes. Then the supernatant was collected and
then stored at −20°C.
Quantitative analysis by HPLC
For MBZ assay, 0.5 ml plasma, cyst wall, cyst fluid and
mice’s tissue samples with ABZ as internal standard was
extracted with Oasis HLB Cartridges (Waters, USA).
The final collection of methanol elution was dried and
redissolved in methanol. All samples were filtrated with
0.45 μm membrane filter before injection.
The system of instrument consisted of a 1525 Binary
HPLC Pumps, a 717 plus auto sampler and a 2457 Dual λ
Absorbance Detector (Waters, USA). The assay of MBZ
was performed in a 5 μm C18 250 × 4.6 mm column
(Beckman Coulter, USA) and a mobile phase containing
350 ml of 0.05 M ammonium sulfate and 650 ml of
methanol at a flow rate of 1 ml/min. The MBZ concen-
tration was measured by its absorbance at a wavelength
of 289 nm. The details and validation of the analytical
methodology can be seen in Additional file 1.
Pharmacokinetic parameters
Using the non-compartmental model present in DAS 2.0
(Drug Analyze System, Shanghai University of T.C.M,
China), the pharmacokinetic parameters of AUC0-t (the
area under the drug concentration-time curve), Cmax
(the peak concentration of the drug) and Tmax (time to
the drug peak concentration) were estimated. The value
of relative bioavailability (F) was calculated by the fol-
lowing formula:
F ¼ AUC0−t of MBZ−OS=AUC0−t of MBZ−1% trangacanth
Influence of MBZ-OS on the liver of E. granulosus-infected
mice
Liver function test
Before the mice were sacrificed for evaluating the treatment
effect of MBZ-OS against secondary cysts of E. granulosus,
the blood sera of 10 mice respectively from MBZ-OS and
MBZ-1% trangacanth at a dose of 25 mg/kg, and untreatedcontrol group were collected and immediately ready for the
liver function test. In order to observe the liver injury of
mice infected with E. granulosus cysts, the blood of normal
mice, which were kept for the same 8 months was also
collected and served as uninfected group. The liver func-
tion test was carried out by Adicon Clinical Laboratories
(Shanghai, China) with Automatic Chemistry Analyzer
640 (OLYMPUS, Japan). The total protein (TP), albumin
(ALB), globulin (GLB), total bilirubin (TBIL), direct biliru-
bin (DBIL), indirect bilirubin (IBIL), alkaline phosphatase
(ALP), alanine transaminase (ALT), aspartate transaminase
(AST) were analyzed with Automatic Chemistry Analyzer
640 (Olympus, Japan).
Histopathology examination
The livers of 5 mice from the same two treated groups,
untreated control group and uninfected group corre-
sponding to liver function tests were rapidly excised,
washed twice with normal saline and fixed in 10% neutral
buffered formal. The fixed samples were dehydrated in
ascending series of ethanol, embedded in paraffin, cut into
5 μm sections, and stained with hematoxylin and eosin
(H + E) for microscopic examination. For statistical pur-
poses, the severity of histopathological changes was mea-
sured on a semi-quantitative scale scored in four categories
according to the intensity of alterations: without alter-
ation (0), slightly altered (1), intermediately altered (2)
and strongly altered (3).
Statistical analysis
The difference of mean cyst weight and liver function
test results were analyzed by ANOVA in SPSS 17.0 and
P < 0.05 was considered statistically significant.
Ethics approval
Animal care and all animal procedures were carried out in
compliance with the Guidelines for the Care and Use of
Laboratory Animals produced by the Shanghai Veterinary
Research Institute. The study was approved by the Ethics
Committee of the Institute of Parasitic Diseases, Chinese
Center for Disease Control and Prevention. The license
number was IPD-2012-2.
Results
Effect against secondary cysts of E. granulosus
In the four groups orally treated with MBZ-OS and
MBZ-1% tragacanth at a daily dose of 12.5 mg/kg and
25 mg/kg for 14 days, the mean cyst weights were all
lower than that of the untreated control. For MBZ-1%
tragacanth groups at 25 mg/kg and 12.5 mg/kg, the cyst
weight reductions were 48.9% and 2.2% respectively
(Table 1). And the difference between MBZ-1% traga-
canth groups and untreated control groups was not
statistically significant (P > 0.05). However, the mean
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than that of the untreated control group (P < 0.05) with
mean cyst weight reductions of 90.2% at 25 mg/kg and
82.6% at 12.5 mg/kg (Table 1). During the experiment, we
had some inevitable loss due to the long- term administra-
tion. One mouse died in the MBZ-1% tragacanth group at
12.5 mg/kg and one in the MBZ-OS group at 25 mg/kg.
But this did not affect the calculation of mean cyst weight.
MBZ concentration in plasma, cyst fluid, cyst wall and
tissues of mice
It can be seen from Figure 1 that, both of the MBZ-OS
and MBZ-1% tragacanth were absorbed by the parasite
and tissues of the mice. After orally administrating MBZ-
1% tragacanth to mice at a single dose of 25 mg/kg, a
concentration peak of 0.27 ± 0.15 μg/ml showed at 0.5 h
post-treatment in the plasma, then the highest MBZ con-
centration of 0.49 ± 0.23 μg/ml at 2 h (Figure 1). Thereafter,
the MBZ concentration declined significantly and main-
tained at low level up to 24 h. On the other hand, a
concentration peak of 0.92 ± 0.01 μg/ml and highest MBZ
concentration of 3.28 ± 0.40 μg/ml were emerged in
plasma after oral administration of MBZ-OS. Obviously,
the MBZ concentration in MBZ-OS group was higher than
MBZ-1% tragacanth. And in MBZ-OS group, the time
reaching to the plasma peaks was somewhat delayed
compared to MBZ-1% tragacanth group.
Similar to that of the plasma, the peak concentration
of MBZ-1% tragacanth was 2.11 ± 1.58 μg/g at 0.25 h
and then maintained about 1 μg/g in hearts. The highest
concentration (2.59 ± 0.68 μg/g) of MBZ-OS emerged at
4 h, and then slowly declined to about 1 μg/g (Figure 1).
As seen in Figure 1, the concentration-time profiles of
cyst fluid and cyst wall were almost same. In detail, the
first concentration peaks of 0.011 ± 0.002 μg/ml and
0.70 ± 0.3 μg/g had been detected in cyst fluid and cyst
wall after 1–2 h post-administration after administrating
MBZ-1% tragacanth, and then the second peaks at 8 h
(0.006 ± 0.001 μg/ml and 0.30 ± 0.27 μg/g, respectively). In
contrast, the MBZ concentration of MBZ-OS increased
with time and the highest concentration peaks of 0.031 ±
0.004 μg/ml and 0.73 ± 0.27 μg/g emerged at 8 h in cyst
fluid and cyst wall. Thereafter, the drug levels declined butTable 1 Mean ± SD (g) and reduction (%) of the hydatid cysts
control and treated groups MBZ-1% and MBZ-OS both dosed
Groups Dose (mg/kg per day × 14 days) No. of m
Untreated control − 17




*P < 0.05 vs. untreated control.still higher than MBZ-1% tragacanth till the end of the
experiment period.
In the liver, the highest MBZ concentrations of
MBZ-OS and MBZ-1% tragacanth were 2.16 ± 3.32 μg/g
and 3.25 ± 4.33 μg/g at 0.25 h. Then the second concen-
tration peaks of 1.12 ± 0.56 μg/g and 1.71 ± 0.74 μg/g were
found at 2 h and 8 h post-administration. According to
the concentration-time profile of the lung, the highest
drug concentration of MBZ-1% tragacanth was 9.05 ±
13.21 μg/g, and 40.8 ± 30.28 μg/g at 2 h for MBZ-OS.
During the 24 h post-administration, the drug concentra-
tions of MBZ-OS were higher than that of MBZ-1% traga-
canth in spleen and kidney, with a delayed time reaching
the drug peak concentration (Figure 1). The peak concen-
tration of MBZ-1% tragacanth was 0.30 ± 0.32 μg/g at 2 h
and then decreased in the brain. For MBZ-OS, there were
two concentration peaks (0.13 ± 0.02 μg/g at 2 h and the
second 0.47 ± 0.03 μg/g at 8 h).
In contrast to the plasma, parasite and other tissues,
the drug concentration of MBZ-1% tragacanth (38.3 ±
44.01 μg/g) in intestine was higher than that of MBZ-OS
(5.04 ± 3.68 μg/g). And at the end of 24 h, the drug con-
centration of MBZ-OS group declined to 0.01 ± 0.00 μg/g
while that of MBZ-1% tragacanth was still as high as
2.47 ± 1.38 μg/g.
Pharmacokinetic parameters of plasma, cyst fluid, cyst
wall and tissues of mice
According to the MBZ concentration-time curve obtained
from E. granulosus-infected mice orally administrated
with MBZ formulations at a single dose of 25 mg/kg,
Tmax, Cmax, AUC0-t and F were calculated and listed in
Table 2. In plasma, Tmax values of MBZ-OS and MBZ-1%
tragacanth were 2.6 ± 1.1 μg/ml and 3.3 ± 1.1 μg/ml,
respectively. But for parasite and tissues, the mean Tmax
values were numerically different between two treated
groups. It was found that the Cmax values in the MBZ-OS
group were 0.3-4.9 times higher than the MBZ-1% traga-
canth group in plasma, cyst fluid, liver, lung, spleen, brain,
nearly the same in kidney and 0.6-4.6 times lower in cyst
wall and intestine. In addition, the AUC values were 1.5-9.3
times of the MBZ-1% tragacanth group in plasma, parasite
and most tissues but not intestine.weigh recovered from infected mice from the untreated
at 12.5 and 25 mg/kg daily during 14 days






Figure 1 Mebendazole (MBZ) concentration in plasma and tissues of E. granulosus infected mice orally administrated with MBZ-OS and
MBZ-1% tragacanth at a single dose of 25 mg/kg.
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Table 2 Pharmacokinetic parameters of MBZ-OS and MBZ-1% tragacanth in plasma and tissues of mice after oral
administration at a single dose of 25 mg/kg
Plasma, Parasite
and Tissues
Mean value (SD) of pharmacokinetic parameters (MBZ-1% tragacanth/MBZ-OS)
Tmax
a (h) Cmax
b (μg/ml or μg/g) AUC0-t
c (μg/ml × h or μg/g × h) Fd
Plasma 2.6 (1.1) 3.3 (1.1) 0.7 (0.2) 4.1 (1.7) 3.8 (1.9) 27.1 (0.9) 7.1
Parasite Cyst wall 0.8 (0.3) 6.7 (2.3) 1.1 (0.7) 0.7 (0.3) 5.8 (2.0) 13.4 (4.1) 2.3
Cyst fluid 1.0 (0) 8.0 (0) 0.011 (0.002) 0.031 (0.004) 0.069 (0.011) 0.50 (0.03) 7.3
Tissues Liver 1.1 (0.9) 3.1 (4.3) 3.1 (2.7) 4.1 (3.8) 10.9 (11.1) 19.4 (3.6) 1.8
Lung 7.3 (7.5) 4.0 (3.4) 12.1 (12.0) 50.2 (14.2) 49.6 (47.6) 459.7 (133.1) 9.3
Spleen 2.1 (1.8) 11.3 (8.1) 4.7 (2.1) 10.6 (1.4) 37.5 (28.0) 135.3 (49.5) 3.6
Kidney 1.2 (0.8) 9.2 (6.1) 7.3 (2.1) 7.6 (2.0) 94.1 (24.4) 137.8 (38.9) 1.5
Intestine 3.0 (1.7) 1.1 (0.9) 44.0 (39.2) 7.8 (1.8) 256.2 (233.9) 28.2 (13.6) 0.1
Heart 13.4 (12.1) 3.5 (4.0) 2.4 (1.4) 3.3 (0.6) 28.2 (4.0) 43.9 (4.1) 1.6
brain 8.7 (7.0) 6.0 (3.5) 0.2 (0.3) 0.5 (0.1) 0.7 (0.3) 3.8 (0.06) 5.4
a: Tmax was time to the drug peak concentration.
b: Cmax was the peak concentration of the drug.
c: AUC0-t was the area under the drug concentration-time curve.
d: F (relative bioaviability) = AUC0-t of MBZ-1% tragacanth/AUC0-t of MBZ-OS.
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Histopathological changes of the liver
After the treatment with MBZ-OS and MBZ-1% traga-
canth at 25 mg/kg, histopathological changes in the liver
of the normal (uninfected), untreated and treated mice
were observed simultaneously (Figure 2, Table 3). Com-
pared with uninfected groups, there was no significant
difference from other groups in histopathological changes
(P > 0.05, Table 3). In uninfected and untreated control
groups, the hepatocytes and other cells of the livers were
normal and systematically arranged but showed light fatty
infiltration. However, fatty infiltration had been seen in all
groups without significant difference. The light swelling of
hepatocytes was only found in the two treated groups
(Figure 2).
Liver function test
As seen in Table 4, the liver function test results suggested
that the IBIL values of the untreated control group and
two treated groups were all significantly increased com-
pared with the uninfected group. In addition, the AST and
ALT values of the untreated control group were also
significantly higher than that of the uninfected group.
However, after the treatment with MBZ-OS or MBZ-1%
tragacanth, the values of these two parameters (AST and
ALT) were decreased and reached to the level of the unin-
fected control. It was also found that the GLB value of the
MBZ-OS was 28.3 ± 2.4 g/L, significantly higher than that
of the other groups.
Discussion
In our previous studies, it was found that, due to the
increase of the drug solubility, suspending the insoluble
MBZ with oily solvents significantly improved thetreatment efficacy against secondary E. granulosus cysts
than MBZ-1% tracangth [18]. Then the optimal MBZ
oily suspension was chosen by comparing the pharmaco-
kinetic parameters, especially the values of Cmax and
AUC0-t (unpublished). At a dose of 25 mg/kg and
12.5 mg/kg, the cyst weight reductions of the MBZ-OS
groups were higher than 80%, while MBZ-1% tragacanth
was lower than 30%. In some studies, 25 mg/kg was con-
sidered as the minimum effective dose for MBZ in the
treatment of mice infected with E. granulosus cysts
[26,34]. However, the lower dosage used in this study
made it possible to reduce the oral dose of MBZ-OS in
the future clinical trials. At present, the current solid
tablet of MBZ is sub-optimal in efficacy, resulting in the
need for higher doses and prolonged duration of treat-
ment (40 mg/kg-50 mg/kg per day in three divided doses
for at least 3–6 months) [9]. With such long term
chemotherapy, the patients hardly continue the treat-
ment as they are more likely to comply with ABZ be-
cause it is more cost-effective and involves fewer tablets.
However, in view of the fact that the effect of MBZ
against E. granulosus metacestodes in vitro and in ex-
perimental therapy proceeded in mice were both better
than ABZ [11,12,26,27], it could be concluded that once
the absorption problem of MBZ is solved , MBZ would
be more widely used with improved clinical cure rate.
The results from the pharmacokinetic analysis of MBZ
in plasma, parasite and tissues of mice proved that the
improved treatment efficacy was resulted from the
higher drug concentration in plasma and parasite. Be-
cause of the special structure of the hydatid cysts, MBZ
could penetrate these cysts by passive diffusion only
[11]. Therefore, the drug concentrations in cyst fluid and
cyst wall were determined by that in the plasma. And in
Table 3 Histopathological changes in the livers of the mice from the uninfected control, untreated control and treated
groups MBZ-1% tragacanth and MBZ-OS (10 mice per group) were observed by microscopy (n = 5)
Histopathologcial Changes Uninfected control group Untreated control group MBZ-1% tragacanth MBZ-OS
Congestion 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Fatty infiltration 0.4 (0.3) 0.8 (0.5)* 0.6 (0.6) 0.6 (0.6)
Hepatocyte swelling 0.0 (0.0) 0.0 (0.0) 0.5 (0.7) 0.4 (0.6)
Inflammatory cell infiltration 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
*P < 0.05 vs. uninfected group.
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parasite increased. That was, the AUC0-t values of
plasma, cyst fluid and cyst wall were 7.1, 7.3 and 2.3
times of that in MBZ-1% tracangth group, while the
Cmax values were 5.9, 2.8 and 0.6 times respectively. It
was also found that the MBZ concentration in cyst fluid
was obviously lower than in plasma after a single admin-
istration of MBZ-OS. However, drug concentration in
cyst fluid would be closed to that in plasma by contin-
ued chemotherapy, so the long time regime is necessary
[35]. In addition, the increased AUC0-t values of cyst
fluid and cyst wall in MBZ-OS group were partially due
to the prolonged Tmax.
In this study, the pharmacokinetic analysis was proceeded
with E. granulosus –infected mice. And the calculated phar-
macokinetic parameters were numerically different from
that of the uninfected mice from our former studies [18].
In details, the Cmax and AUC0-t values of infected miceFigure 2 Histopathological changes of liver. H + E, fatty infiltration (large
infected mice without treatment; C. E. granulosus infected mice treated with MBwere lower than that of uninfected mice with prolonged
Tmax. Similarly, Witassek et al. reported the MBZ plasma
concentration of the E. multilocularis-infected jirds was
lower than the non-infected ones [36]. It seems that the E.
granulosus infection might influence the MBZ metabolism
in mice. However, the mechanism would be clarified by
further study on this topic. In our previous studies, the
Tmax values of MBZ oily suspensions changed a little com-
pared with the MBZ-1% tracangth [18]. These results
suggested that the absorption rate which is relevant to the
value of Tmax, still limit the absorption of MBZ into the
plasma.
After oral administration of MBZ-OS, the drug concen-
trations in lung, spleen kidney, heart and brain were
higher than that of the MBZ-1% tragacanth. However,
contributed by the accumulated indissolvable parent drug,
the Cmax value of MBZ-1% tragacanth was nearly 6 times
of the new formulation in the intestine. On the otherarrow), hepatocyte swelling (small arrow) A. Normal mice; B. E. granulosus
Z-1% tragacanth; D. E. granulosus infected mice treated with MBZ-OS.
Table 4 Outcomes of liver function tests for mice from the uninfected control, untreated control and treated groups
MBZ-1% tragacanth and MBZ-OS (10 mice per group)
Parameters Definitions Units Uninfected control Untreated control MBZ-1% tracangth MBZ-OS
T-BIL Total bilirubin umol/L 2.3 (0.8) 2.8 (0.4) 3.2* (0.8) 2.9 (0.5)
D-BIL Direct bilirubin umol/L 0.5 (0.3) 0.3 (0.1) 0.4 (0.2) 0.3 (0.1)
I-BIL Indirect bilirubin umol/L 1.8** (0.7) 2.6* (0.4) 2.8* (0.7) 2.6* (0.5)
TP Total protein g/L 55.2 (1.9) 57.7 (2.9) 58.2 (3.8) 63.1** (3.2)
ALB Albumin g/L 31.6 (1.7) 32.2 (1.6) 32.7 (2.0) 34.8 (2.0)
GLB Globulin g/L 23.6 (0.8) 25.6 (3.3) 25.5 (3.0) 28.3** (2.4)
A/G 1.3 (0.1) 1.3 (0.2) 1.3 (0.2) 1.2 (0.4)
AST Aspartate transaminase U/L 122.8** (32.1) 173.7* (107.0) 113.9** (16.9) 100.8** (14.7)
ALT Alanine transaminase U/L 45.1** (21.8) 81.0* (48.8) 35.7 ** (17.7) 27.6 ** (4.5)
AST/ALT 3.0 (0.8) 2.3 (0.7) 3.6 ** (1.2) 3.7** (0.7)
ALP Alkaline phosphatase U/L 86.2 (29.6) 67.4 (14.0) 74.5 (28.8) 80.7 (19.1)
*P < 0.05 vs. uninfected group.
**P < 0.05 vs. untreated control group.
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circulation. It was found that the Cmax and AUC0-t values
of MBZ-OS in liver and kidney were not changed as much
as in plasma. As the crucial metabolism and elimination or-
gans, liver and kidney might clear away MBZ by their cor-
responding functions. However, in lung, spleen and brain,
Cmax and AUC0-t of MBZ-OS were significantly increased
than MBZ-1% tragacanth. Given that the high drug concen-
tration in tissues may bring some safety concern, MBZ-OS
was orally given to 10 mice (5 female mice and 5 male
mice) at 5 g/kg. After 7 days’ observation, no mice died.
Although no acute toxicity of MBZ-OS had been seen in
this experiment, a long-term toxicity test is still necessary
in the following study.
In the treatment of hydatid diseases, the benzimidazoles
were considered safe with occasional side effects [37-39].
In China, albendazole-emulsion is the dominant clinical
formulation for patients with echinococcosis. However,
patients often feel uncomfortable in the liver after taking
albendazole-emulsion on a daily basis. This may be due to
the drug side effects or oils added in formulation. Consid-
ering that oils were also added in MBZ-OS, then the influ-
ence of this MBZ new formulation on the liver of mice
was also observed in this study. At 25 mg/kg, the hepato-
cytes of mice showed light fatty infiltration in all the
experimental groups and the light swelling was found in
both of the treated groups. So it was suggested that the
long term taking of MBZ affected the hepatocytes. But
comparing with the uninfected group, the changes were
not significant. Hence, it could be preliminary concluded
that the liver of mice were not seriously injured by taking
MBZ and MBZ-OS than the raw materials. In order to ob-
tain more information about liver toxicity, the liver func-
tion test was carried out by collecting the serum of the
uninfected, the untreated control, MBZ-1% tragacanthand MBZ-OS group. Unlike the results from the histo-
pathological changes, some parameters showed signifi-
cantly difference between uninfected group and the other
groups. In details, the values I-BIL, AST and ALT of
infected mice without treatment were statistically higher
than that of uninfected mice. And the orally administra-
tion with MBZ did not change the increased I-BIL values
but reduced the values of AST and ALT. In addition, the
GLB values of the MBZ-OS were significantly increased
after taking MBZ-OS. Due to the lack of the normal
ranges for KM mice, the real injury of the liver could not
be concluded from the liver function test. However, if the
significant differences of these parameters between unin-
fected mice and infected could make sense, I-BIL, AST
and ALT values might be used as the indicators for
diagnosing the hydatid diseases. But this assumption
needed verification with abundant clinical cases.
Conclusion
In the present study, a promising new formulation of
MBZ for treatment of hydatid diseases was developed.
This MBZ-OS improved the treatment efficacy in E.
granulosus-infected mice and no serious injury on the
liver was observed. However, based on the increased
MBZ concentration, the lung and spleen toxicity should
be paid more attention in a future study. For the clinical
trials in healthy volunteers and patients, further re-
searches will be required to apply under the support of
government and pharmaceutical companies.
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